Disc Medicine Inc. (IRON)
NASDAQ (NMS) NASDAQ (NMS) Primary 
LSE Summary
Ironveld shares jump 32% at 0.025p as processing plant hits sustained production
Shares in Ironveld PLC (AIM:IRON) jumped 32% to 0.025p after the mining developer said its processing plant had reached sustained production and secured strong commercial demand. Ironveld, an AIM-listed company producing strategic metals for mineral processing, said its dense media separation plant was now running continuously for 16 hours a day on a double shift.
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook Transcript
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook Transcript
Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge
Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains.
Disc Medicine Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 40 | $2,115.92 | $3,020 | $904.08 | 42.73% |
| BG Bart Gancher Intech Investment Management LLC | 5,868 | $352,199.28 | $441,909.69 | $89,710.41 | 25.47% |
 John H. Burbank III Passport Capital LLC | 349,657 | $19.46M | $26.33M | $6.87M | 35.31% |
 Anthony Scaramucci SkyBridge Capital II LLC | 536,000 | $31.63M | $40.44M | $8.81M | 27.84% |
 Didric Cederholm Lion Point Capital LP | 8,100 | $439,388 | $609,998.04 | $170,610.04 | 38.83% |
Disc Medicine Inc. (IRON) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Disc Medicine Inc. ever had a stock split?
Disc Medicine Inc. Profile
| Biotechnology Industry | Healthcare Sector | John D. Quisel CEO | NASDAQ (NMS) Exchange | 254604101 CUSIP |
| US Country | 155 Employees | - Last Dividend | 30 Dec 2022 Last Split | 12 Aug 2020 IPO Date |
Overview
Disc Medicine, Inc., along with its subsidiaries, is a pioneering force in the biopharmaceutical realm, focusing its efforts on the clinical-stage development, discovery, and eventual commercialization of groundbreaking treatments aimed at tackling severe hematologic diseases within the United States. Established in 2017 and operating from its headquarters in Watertown, Massachusetts, Disc Medicine has strategically curated a robust portfolio consisting of both clinical-stage and preclinical product candidates. These candidates are specifically designed to target and modulate the fundamental biological pathways crucial to the formation and function of red blood cells, with a keen focus on heme biosynthesis and iron homeostasis, underscoring the company's commitment to addressing unmet needs in the field of hematologic health.
Products and Services
- Bitopertin: Aimed at treating a spectrum of erythropoietic porphyrias, including conditions such as erythropoietic protoporphyria and X-linked protoporphyria, as well as diamond-blackfan anemia. Bitopertin represents a novel approach in tackling these rare but debilitating diseases by potentially modifying the pathways associated with the production and function of red blood cells.
- DISC-0974: This candidate is tailored for patients suffering from anemia associated with myelofibrosis, as well as those grappling with anemia of chronic kidney disease. DISC-0974 exemplifies Disc Medicine's effort to combat these widespread conditions by targeting the underlying biological mechanisms, offering hope for improved patient outcomes in these areas.
- DISC-3405: Focused on the treatment of polycythemia vera and other related hematologic disorders, DISC-3405 aims to provide a solution for diseases characterized by an overproduction of red blood cells. Through its innovative design, DISC-3405 seeks to bring balance to red blood cell production and function, addressing a critical need in the management of these conditions.
- DISC-0998 (Preclinical): At the preclinical stage, DISC-0998 is being developed to address anemia associated with inflammatory diseases. This program highlights Disc Medicine's forward-thinking approach in expanding its portfolio to include treatments that cater to a broader range of hematologic disorders, especially those linked to inflammation, further solidifying its commitment to advancing hematologic health.
